KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$0.07.

  • Neogenomics' EPS (Basic) rose 4166.67% to -$0.07 in Q4 2025 from the same period last year, while for Dec 2025 it was -$0.83, marking a year-over-year decrease of 3387.1%. This contributed to the annual value of -$0.84 for FY2025, which is 3548.39% down from last year.
  • Neogenomics' EPS (Basic) amounted to -$0.07 in Q4 2025, which was up 4166.67% from -$0.21 recorded in Q3 2025.
  • Neogenomics' 5-year EPS (Basic) high stood at $0.64 for Q2 2021, and its period low was -$0.4 during Q1 2022.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.19 (2021), whereas its average is -$0.17.
  • Over the last 5 years, Neogenomics' EPS (Basic) had its largest YoY gain of 116666.67% in 2021, and its largest YoY loss of 95000.0% in 2021.
  • Quarter analysis of 5 years shows Neogenomics' EPS (Basic) stood at -$0.35 in 2021, then surged by 48.57% to -$0.18 in 2022, then soared by 38.89% to -$0.11 in 2023, then fell by 9.09% to -$0.12 in 2024, then soared by 41.67% to -$0.07 in 2025.
  • Its EPS (Basic) stands at -$0.07 for Q4 2025, versus -$0.21 for Q3 2025 and -$0.35 for Q2 2025.